Mor­phoSys files for $150M IPO to fu­el its hope­ful DL­B­CL drug launch

Mor­phoSys, a pub­lic com­pa­ny in Ger­many, is shoot­ing for a dual list­ing of its shares, hop­ing to raise $150 mil­lion by head­ing to the Nas­daq. The com­pa­ny is stock­pil­ing cash to take its in­ves­ti­ga­tion­al an­ti-CD19 an­ti­body, called MOR208, all the way to the mar­ket.

Mor­phoSys al­ready has its shares list­ed on the Ger­man stock ex­change, where it draws a $3 bil­lion val­u­a­tion. It brought in about $83 mil­lion in rev­enue last year, and has a good bit of cash al­ready in the bank. The com­pa­ny says it’s gath­er­ing its re­sources, along with this new IPO in the states, to sink $225 mil­lion in­to the de­vel­op­ment of MOR208 and an ad­di­tion­al $90 mil­lion to build out its com­mer­cial in­fra­struc­ture so Mor­phoSys can han­dle MOR208’s launch.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER